Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2024 06:45 ET | Source: Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

Paratek Announces Positive Efficacy Data for NUZYRA®, Triggering Additional Procurement under BARDA Project BioShield Contract
January 16, 2024 09:00 ET | Source: Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer

Paratek Pharma Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer, Christopher Bostrom to Chief Financial Officer
December 13, 2023 08:53 ET | Source: Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
September 07, 2023 15:34 ET | Source: Paratek Pharmaceuticals, Inc.

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of...

keyboard_arrow_left Previous Page